BIB Performance — ProShares Ultra Nasdaq Biotechnology
Data updated: 2026-08-14
BIB returned +6.15% year to date and +98.53% over one year to May 2026. Annualised returns are +18.55% over 3 years and +0.58% over 5 years. Against its Trading - Leveraged category average the fund came out behind over three years but ahead over one: $100 invested three years ago grew to $167, against $173 for the category, and to $199 over one year, against $137. Volatility over the past three years was 32.71% a year. In the 12 months to May 2026 the fund lost a net $12.0M, and assets reached $73.65M.
BIB Growth of $100
What $100 invested in ProShares Ultra Nasdaq Biotechnology grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Trading - Leveraged category average over the same months.
| Period | BIB | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $199 | $137 |
| 3 years (Jun 2023 – May 2026) | $167 | $173 |
| 5 years (Jun 2021 – May 2026) | $103 | $155 |
| Since data start (Sep 2019 – May 2026) | $190 | $181 |
BIB Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +6.15% |
| 1 year | +98.53% |
| 3 years (annualised) | +18.55% |
| 5 years (annualised) | +0.58% |
BIB Annual Returns
Calendar-year total returns of ProShares Ultra Nasdaq Biotechnology, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +6.15% |
| 2025 | +59.34% |
| 2024 | −10.00% |
| 2023 | −1.28% |
| 2022 | −28.64% |
| 2021 | −5.91% |
| 2020 | +39.74% |
| 2019 (Sep–Dec) | +35.03% |
BIB Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.3% | +6.0% | −7.5% | +0.1% | +3.8% | — | — | — | — | — | — | — |
| 2025 | +9.8% | −1.1% | −12.2% | −1.3% | −9.4% | +6.8% | +10.4% | +9.3% | +8.1% | +20.0% | +16.9% | −4.4% |
| 2024 | −0.1% | +1.3% | −0.4% | −12.4% | +11.2% | +6.2% | +12.7% | +0.9% | −5.1% | −5.5% | −1.1% | −14.4% |
| 2023 | +6.3% | −13.1% | +1.5% | +2.3% | −5.9% | −0.5% | +1.9% | −1.3% | −8.1% | −13.5% | +9.1% | +26.1% |
| 2022 | −23.0% | −8.4% | +8.0% | −19.2% | −3.9% | +0.8% | +7.6% | −3.0% | −5.9% | +17.2% | +11.3% | −6.7% |
| 2021 | +12.3% | −5.0% | −9.3% | +5.6% | −4.2% | +16.3% | −0.8% | +7.8% | −9.8% | −4.1% | −7.9% | −3.1% |
| 2020 | −11.3% | −0.1% | −15.0% | +30.3% | +16.9% | +2.6% | −3.9% | +1.5% | −1.0% | −7.9% | +22.7% | +8.9% |
| 2019 | — | — | — | — | — | — | — | — | −6.8% | +15.5% | +23.7% | +1.4% |
BIB Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 32.71%
- 3-year Sharpe ratio: 0.43 (vs 4.5% risk-free rate)
- Best month: +26.10% (Dec 2023)
- Worst month: −14.45% (Dec 2024)
BIB Fund Flows
Monthly money in and out of ProShares Ultra Nasdaq Biotechnology, from SEC Form N-PORT.
- 12-month net flow: −$12.0M
- 12-month gross sales (incl. reinvestments): $10.7M
- Sales ÷ redemptions: 0.47×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $0 | $4.8M | −$4.8M |
| Apr 2026 | $0 | $5.1M | −$5.1M |
| Mar 2026 | $0 | $4.0M | −$4.0M |
| Feb 2026 | $0 | $889K | −$889K |
| Jan 2026 | $1.6M | $1.7M | −$59K |
| Dec 2025 | $788K | $794K | −$6K |
| Nov 2025 | $7.6M | $1.6M | $6.1M |
| Oct 2025 | $643K | $680K | −$36K |
| Sep 2025 | $0 | $0 | $0 |
| Aug 2025 | $0 | $2.3M | −$2.3M |
| Jul 2025 | $0 | $484K | −$484K |
| Jun 2025 | $0 | $457K | −$457K |
BIB Assets Under Management
Net assets of ProShares Ultra Nasdaq Biotechnology by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $73.65M |
| 2026-02-28 | $91.71M |
| 2025-11-30 | $87.74M |
| 2025-08-31 | $53.59M |
| 2025-05-31 | $44.30M |
| 2025-02-28 | $61.55M |
| 2024-11-30 | $77.49M |
| 2024-08-31 | $94.29M |
| 2024-05-31 | $88.27M |
| 2024-02-29 | $96.82M |
| 2023-11-30 | $74.77M |
| 2023-08-31 | $90.22M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.